Please use this identifier to cite or link to this item:
|Hydration effects on the efficacy of the Epidermal growth factor receptor kinase inhibitor afatinib
Pradhan, Mohan R.
Tan, Eng Huat
Tan, Daniel Shao-Weng
|Kannan, S., Pradhan, M. R., Tiwari, G., Tan, W.-C., Chowbay, B., Tan, E. H., et al. (2017). Hydration effects on the efficacy of the Epidermal growth factor receptor kinase inhibitor afatinib. Scientific Reports, 7, 1540-.
|Small molecules targeting the EGFR tyrosine kinase domain have been used with some success at treating patients with non-small cell lung cancer driven by activating mutations in the kinase domain. The initial class of inhibitors displaced ATP noncovalently but were rendered ineffective due to the development of resistance mutations in the kinase domain. These were overcome by the development of covalent inhibitors such as afatinib which also bind in the ATP pocket. However pooled analysis of two recent clinical trials LUX-3 and LUX-6 demonstrated an unprecedented overall survival benefit of afatinib over chemotherapy for the EGFR19del, but not the EGFRL858R. In the current study we use modelling and simulations to show that structural constraints in EGFR19del deletion result in significantly attenuated flexibilities in the binding pocket resulting in strong hydrogen and halogen bonds with afatinib in the EGFR19del; these constraints are modulated by buried water and result in the differential affinities of afatinib for the different mutants. SNP analysis of residues surrounding the buried water points to the likelihood of further differential effects of afatinib and provides a compelling case for investigating the effects of the SNPs towards further stratification of patients for ensuring the most effective use of afatinib.
|School of Biological Sciences
|© 2017 The Author(s) (Nature Publishing Group). This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/
|Appears in Collections:
|SBS Journal Articles
Files in This Item:
|Hydration effects on the efficacy of the Epidermal growth factor receptor kinase inhibitor afatinib.pdf
Updated on Feb 27, 2024
Web of ScienceTM
Updated on Oct 25, 2023
Page view(s) 50433
Updated on Mar 4, 2024
Updated on Mar 4, 2024
Items in DR-NTU are protected by copyright, with all rights reserved, unless otherwise indicated.